BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Bladder and urothelial cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for urothelial carcinoma: 145 (97 sponsors; 16 newly posted in the last 180 days, 8 stopped in the last 180 days; 9 new-entrant sponsors). Momentum score 11, rank 62 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 47, Phase 2 56, Phase 3 26, Phase 4 1, N/A 14.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience Co., Ltd. | 5 | P2 3, P3 2 | 0 | 1 |
| UroGen Pharma Ltd. URGN | 3 | P3 2, NA 1 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 6 | P2 5, P3 1 | 0 | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 6 | P3 1, P2 3, P1 2 | 1 | 2 |
| Eli Lilly and Company LLY | 5 | P2 1, P3 1, P1 3 | 1 | 2 |
| Astellas Pharma Global Development, Inc. | 3 | P4 1, P3 1, P2 1 | 0 | 1 |
| BeiGene | 3 | P1 1, P2 1, P3 1 | 0 | 0 |
| Daiichi Sankyo | 3 | P2 2, P3 1 | 1 | 0 |
| Seagen, a wholly owned subsidiary of Pfizer | 3 | P2 2, P3 1 | 0 | 2 |
| AstraZeneca AZN | 2 | P2 1, P3 1 | 1 | 0 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| EMD Serono Research & Development Institute, Inc. | 2 | P3 1, P2 1 | 0 | 1 |
| Janssen Research & Development, LLC | 2 | P2 1, P3 1 | 0 | 1 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| SystImmune Inc. | 2 | P1 1, P3 1 | 1 | 0 |
| CG Oncology, Inc. CGON | 1 | P3 1 | 0 | 0 |
| Protara Therapeutics TARA | 1 | P3 1 | 0 | 0 |
| Relmada Therapeutics, Inc. RLMD | 1 | P3 1 | 0 | 0 |
| RemeGen Co., Ltd. | 1 | P3 1 | 0 | 1 |
| Summit Therapeutics SMMT new entrant | 1 | P3 1 | 1 | 0 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Taiho Oncology, Inc. | 1 | P3 1 | 0 | 1 |
| Vasgene Therapeutics, Inc | 1 | P3 1 | 0 | 0 |
| Verity Pharmaceuticals Inc. | 1 | P3 1 | 0 | 0 |
| ImmunityBio, Inc. IBRX | 3 | P2 2, P1 1 | 0 | 0 |
New-entrant sponsors: Summit Therapeutics.
Recently stopped trials
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT03444701 Eisai Co., Ltd. - terminated: The trial was prematurely terminated due to the sponsor's decision. A Study of E7130 in Participants With Solid Tumors
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- NCT06714617 SystImmune Inc. - terminated: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the i Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- NCT05014139 Astellas Pharma Global Development, Inc. - terminated: Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, eth A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- NCT03869190 Hoffmann-La Roche - terminated: Study was closed early as the sponsor decided not to continue development of certain treatment combinations. Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Ur
- NCT06022757 Evopoint Biosciences Inc. - terminated: Strategic decision by Sponsor. Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Theralase® Technologies Inc. TLTFF | NCT03945162 Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | recruiting | 90 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05965856 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | Urothelial Carcinoma; Solid Tumor | recruiting | 52 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06405425 A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | Urothelial Carcinoma | recruiting | 52 |
| 2026-12-11 est. | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04879329 A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Urothelial Carcinoma | recruiting | 372 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-30 est. | P3 | Janssen Research & Development, LLC | NCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Urinary Bladder Neoplasms | active not recruiting | 518 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P3 | Pfizer PFE | NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors | active not recruiting | 77 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Urothelial Carcinoma; HER2-expressing | recruiting | 452 |
| 2026-12-31 est. | P2 | Hoffmann-La Roche | NCT05645692 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Met | Urothelial Cancer | active not recruiting | 204 |
| 2026-12-31 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06079112 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | recruiting | 100 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-29 est. | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | active not recruiting | 412 |
| 2027-01-31 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99 | Urinary Bladder Neoplasms | active not recruiting | 520 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | ImmunityBio, Inc. IBRX | NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | not yet recruiting | 20 |
| 2026-11 est. | P3 | CG Oncology, Inc. CGON | NCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma | active not recruiting | 367 |
| 2026-11 est. | P1/P2 | Tyra Biosciences, Inc TYRA | NCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carc | active not recruiting | 310 |
| 2026-09-30 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Non-Muscle Invasive Bladder Cancer | completed | 35 |
| 2026-09-30 est. | P1/P2 | ImmunityBio, Inc. IBRX | NCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer | active not recruiting | 369 |
| 2026-09 est. | P3 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06196736 A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | Advanced Urothelial Carcinoma | recruiting | 432 |
| 2026-07 est. | P3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | recruiting | 402 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-01 | P3 | AstraZeneca AZN | NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | active not recruiting | 1246 |
| 2026-06 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06823427 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Urothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Urothelial Carci | recruiting | 60 |
| 2026-06 est. | P2 | Vaneltix Pharma, Inc. | NCT06394830 Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis; Bladder Pain Syndrome | recruiting | 50 |
| 2026-06 est. | P2 | Vaneltix Pharma, Inc. | NCT05737121 Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS | Interstitial Cystitis; Bladder Pain Syndrome | recruiting | 120 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "urothelial carcinoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.